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Vancomycin is a glycopeptide antibiotic that used in the treat-
ment of severe infections with pathogens such as Staphylo-
coccus  and Streptococcus spp. Following intravenous
administration, vancomycin is poorly metabolized and is
mainly excreted unchanged in urine. Total body clearance is
thus dependent on the kidney, and is correlated with
glomerular filtration rate and creatinine clearance [1]. Elimina-
tion of the agent is slowed in patients with renal insufficiency.
Accumulation of vancomycin may thus occur and may lead to
toxic side effects if the dosage is not modified in accordance
with the degree of renal failure. Furthermore, vancomycin has
a low volume of distribution (0.6 l/kg), a low protein-bound
fraction (50%) and a low molecular weight (1449 Da) [2],
suggesting that it can easily diffuse through dialysis mem-
branes.
We synthesized results from studies on vancomycin dialyz-
ability in different types of membranes and with different dialy-
sis techniques (intermittent and continuous). The aim of the
present review is not to detail the pharmacokinetics of van-
comycin in dialysis patients but to establish guidelines for
handling this drug in such patients. The fundamental principle
for the use of vancomycin in dialysis patients is that the drug
should only be administered when the plasma concentration
is too low to be effective. However, guidelines for appropriate
plasma sampling schedules are not available. We therefore
indicate how and when plasma concentrations of vancomycin
should be determined in dialysis patients. Finally, administra-
tion technique is not discussed here because the ideal tech-
nique is not clearly established [3].
Vancomycin pharmacokinetics in renal
impairment
Renal excretion of vancomycin is altered in patients with renal
insufficiency. The manufacturer of Vancocin® (Eli Lilly and
Co., Indianapolis, IN, USA; reviewed April 2000) has reported
that, in anephric patients, the average vancomycin elimination
half-life is 7.5 days, whereas it is 4–6 hours in patients with
normal renal function. It has also been reported that total
body clearance of vancomycin is correlated with creatinine
clearance in patients with altered renal function [4]. Although
it is clear that renal clearance of vancomycin is decreased in
patients with renal failure, it has also been suggested that
nonrenal clearance of vancomycin, which usually accounts for
approximately 30% (40 ml/min) of total clearance in patients
with normal renal function, is reduced to as low as 5–6
ml/min in patients with terminal renal insufficiency [1,5].
While the mechanisms of this reduction are still unidentified,
inhibition of vancomycin metabolism by uraemic toxins is sus-
pected [6].
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Abstract
Following intravenous administration, vancomycin is poorly metabolized and is mainly excreted
unchanged in urine. Total body clearance is thus dependent on the kidney, and is correlated with
glomerular filtration rate and creatinine clearance. Accumulation of vancomycin in patients with renal
insufficiency may therefore occur, and this may lead to toxic side effects if dosage is not modified
according to the degree of renal failure. Furthermore, vancomycin easily diffuses through dialysis
membranes. The aim of the present review is to establish guidelines for handling this drug in such
patients. We indicate how and when plasma concentrations of vancomycin should be determined in
dialysis patients.
Keywords: haemodialysis, vancomycinCritical Care    August 2002 Vol 6 No 4 Launay-Vacher et al.
Because both renal and nonrenal vancomycin clearances are
reduced in patients with impaired renal function, accumula-
tion of unchanged active drug in plasma is likely to occur. For
this reason, application of existing nomograms or equations
for adjustment of vancomycin dosage in patients with renal
impairment [1,5,7] should be accompanied by monitoring of
plasma vancomycin levels [8,9]. These nomograms or equa-
tions were established on the basis of decline in renal clear-
ance, and do not take into account the decline in nonrenal
clearance. Therefore, their application in patients with com-
promised renal function may result in an insufficient reduction
in dose and may lead to toxicity. It has been suggested that a
vancomycin plasma concentration of 80 µg/ml would be a
reliable level for the toxicity threshold [10]. However, it should
be pointed out that the toxic serum level of vancomycin has
not yet been precisely determined, and serum concentrations
of vancomycin as high as 60–70 µg/ml may also be toxic in
some patients, depending on the particular clinical situation
or associated drugs. Furthermore, it has recently been shown
that nephrotoxicity might be a marker of failure of vancomycin
treatment [3].
The major adverse effects of vancomycin are ototoxicity and
nephrotoxicity. The relationship between vancomycin-induced
ototoxicity and plasma concentration of the drug (peak or
trough levels) is still undergoing investigation. However, van-
comycin-induced nephrotoxicity has been clearly related to
drug plasma concentrations. In a study involving 198 cancer
patients administered vancomycin for treatment of Gram-pos-
itive bacteraemia, Kralovicova and coworkers [11] retrospec-
tively compared occurrence of vancomycin-related
nephrotoxicity with vancomycin trough serum levels. Trough
vancomycin levels greater than 15 µg/ml were associated
with significantly more nephrotoxicity. Those investigators
concluded that maintenance vancomycin doses should be
administered according to the value of the trough level (i.e.
maintaining the trough level <15 µg/ml).
In patients with terminal renal insufficiency undergoing
haemodialysis, whether intermittent or continuous, and receiv-
ing vancomycin therapy, elimination of the drug during the
procedure must be considered when establishing the dosing
schedule.
Table 1
Vancomycin clearance in continuous or chronic haemodialysis: data from the literature.
Reference n Dialysis Membrane CLHD (ml/min) CLER (ml/min)
[13] 16 CAVHDF PAN 6.9–15.4 ND
[14] 5 CVVH AN 5.8–13.4 ND
[14] 5 CVVH PMMA 7.5–27 ND
[14] 5 CVVH PS 5.2–22.1 ND
[15] 12 HD PS 76 ND
[15] 15 HD PAN 55 ND
[15]* 8 HD C 15 ND
[16] 5 HD PS 130.7 ND
[17]* 6 HD C 9.6 ND
[17] 6 HD PS 44.7–85.2 ND
[18] 12 HD PS 120 8.5
[19] 26 HD CT, PS, PMMA 83 ND
[20]* 8 HD C 9.7 5.2
[20] 8 HD PAN 58.4 5.2
[21] 8 HD PS 108.5 ND
[22] 6 HD CT 49.2–111.4 ND
[23] 7 HD PAN 45.7 <5
[23] 6 HD CA 43.3 <5
*Data from studies performed with cuprophan membranes. AN, acrylonitrile; C, cuprophan; CA, cellulose acetate; CAVH, continuous arteriovenous
haemodialysis; CAVHDF, continuous arteriovenous haemodiafiltration; CLER, extrarenal clearance; CLHD, haemodialysis clearance; CT, cellulose
triacetate; CVVH, continuous venovenous haemodialysis; HD, haemodialysis; ND, not determined; PA, polyamide; PAN, polyacrylonitrile; PMMA,
polymethylmethacrylate; PS, polysulfone.Vancomycin in intermittent haemodialysis
(chronic haemodialysis)
Several studies have been reported (Table 1). The two major
elements that can be concluded from analysis of these
studies are as follows: vancomycin is not significantly dialyz-
able when haemodialysis is performed using a low flux mem-
brane such as cuprophan; and vancomycin is significantly
dialyzable when haemodialysis is performed using a high flux
membrane such as polysulfone, polyacrylonitrile and poly-
methylmethacrylate.
Studies of the pharmacokinetics of vancomycin in patients
undergoing haemodialysis with high flux membranes demon-
strated that there is a rebound in vancomycin plasma concen-
trations at the end of the session. The plasma profile of
vancomycin concentrations versus time indicates that con-
centrations decrease dramatically during the session and
then increase when the session is stopped for 3–6 hours
(Fig. 1). This rebound may result from drug recirculation from
plasma protein binding sites. Recirculation from peripheral
compartments is less likely to occur because of the low van-
comycin volume of distribution, indicating that the drug
remains mainly in plasma. This rebound may be clinically sig-
nificant, and it must be taken into account when determining
vancomycin trough levels. Subsequently, it is recommended
that determination of vancomycin trough levels in patients
undergoing chronic haemodialysis should be performed
before the haemodialysis session (Table 2).
Vancomycin in continuous haemodialysis
Continuous renal replacement therapy increases total body
clearance of vancomycin. However, quantification of van-
comycin removal is difficult to estimate, and it is thus also rec-
ommended that plasma levels of the drug be monitored.
When a continuous technique is used, there is no rebound in
vancomycin plasma concentration. Total body clearance of
vancomycin is almost constant, and determination of trough
levels may be performed at any time while continuous
haemodialysis is being performed (Table 2). However, if dialy-
sis is stopped and if vancomycin treatment must be contin-
ued, then the plasma concentration of vancomycin 4–6 hours
after stopping haemodialysis should be determined before
any readministration of the drug (Table 2).
Conclusion
Vancomycin is effectively removed when haemodialysis is
performed with high flux membranes. Maintenance doses
should be administered according to the plasma trough
levels, as determined before the session when the patient is
on chronic intermittent haemodialysis, at any time for continu-
ous haemodialysis, and 6 hours after the end of haemodialy-
sis when continuous therapy is stopped and vancomycin
treatment is continued.
Vancomycin therapy is widely used in patients with
decreased renal function, and serum levels of this agent must
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Figure 1
Vancomycin pharmacokinetic profile during chronic haemodialysis:
evidence for a postsession rebound in plasma concentration.
Reproduced with permission from Welage et al. [22].
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Table 2
Vancomycin dosage and administration in patients on haemodialysis
Initial dose 
Dialysis Membrane (intravenous) Maintenance doses
Chronic haemodialysis High flux 1 g Vancomycin maintenance doses range from 500 mg to 1 g. Maintenance 
doses should be administered according to plasma vancomycin 
concentration, as determined from blood samples drawn before a session.
Continuous haemodialysis High flux 1 g Vancomycin maintenance doses range from 500 mg to 1 g. Maintenance 
doses should be administered according to plasma vancomycin 
concentration, as determined from blood samples that may be drawn at any 
time during continuous haemodialysis. When the dialysis technique is 
discontinued and if vancomycin treatment must be continued, then the 
following maintenance dose should be administered according to plasma 
vancomycin concentration, as determined from a blood sample drawn at 
least 6 hours after the end of dialysis.be closely monitored in such patients in order to avoid toxicity
and subtherapeutic levels, in particular because emergence
of resistance to glycopeptide antibiotics has been noted [12].
Competing interests
None declared.
References
1. Moellering RC Jr, Krogstad DJ, Greenblatt DJ: Vancomycin
therapy in patients with impaired renal function: a nomogram
for dosage. Ann Intern Med 1981, 94:343-346.
2. Dollery C: Vancomycin. In Therapeutic Drugs, 2nd ed. London:
Churchill Livingstone; 1999:V6-V10.
3. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B,
Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D:
Continuous versus intermittent infusion of vancomycin in
severe Staphylococcal infections: prospective multicenter ran-
domized study. Antimicrob Agents Chemother 2001, 45:2460-
2467.
4. Nielsen HE, Hansen HE, Korsager B, Skov PE: Renal excretion
of vancomycin in kidney disease. Acta Med Scand 1975, 197:
261-264.
5. Matzke GR, McGory RW, Halstenson CE, Keane WF: Pharmaco-
kinetics of vancomycin in patients with various degrees of
renal function. Antimicrob Agents Chemother 1984,  25:433-
437.
6. Macias WL, Mueller BA, Scarim SK: Vancomycin pharmacoki-
netics in acute renal failure: preservation of nonrenal clear-
ance. Clin Pharmacol Ther 1991, 50:688-694.
7. Lake KD, Peterson CD: A simplified dosing method for initiat-
ing vancomycin therapy. Pharmacotherapy 1985, 5:640-644.
8. Andres I, Lopez R, Pou L, Pinol F, Pascual C: Vancomycin moni-
toring: one or two serum levels? Ther Drug Monit 1997, 19:
614-619.
9. Mulhern JG, Braden GL, O’Shea MH, Madden RL, Lipkowitz GS,
Germain MJ: Trough serum vancomycin levels predict the
relapse of gram-positive peritonitis in peritoneal dialysis
patients. Am J Kidney Dis 1995, 25:611-615.
10. Bailie GR, Neal D: Vancomycin ototoxicity and nephrotoxicity.
A review. Med Toxicol 1988, 3:376-386.
11. Kralovicova K, Spanik S, Halko J, Netriova J, Studena-Mrazova M,
Novotny J, Grausova S, Koren P, Krupova I, Demitrovicova A,
Kukuckova E, Krcmery V Jr: Do vancomycin serum levels
predict failures of vancomycin therapy or nephrotoxicity
incancer patients? J Chemother 1997, 9:420-426.
12. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robin-
son-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis
WR: Emergence of vancomycin resistance in Staphylococcus
aureus. N Engl J Med 1999, 340:493-501.
13. Bellomo R, Ernest D, Parkin G, Boyce N: Clearance of van-
comycin during continuous arteriovenous hemodiafiltration.
Crit Care Med 1990, 18:181-183.
14. Joy MS, Matzke GR, Frye RF, Palevsky PM: Determinants of van-
comycin clearance by continuous venovenous hemofiltration
and continuous venovenous hemodialysis. Am J Kidney Dis
1998, 31:1019-1027.
15. Alwakeel J, Najjar TA, al-Yamani MJ, Huraib S, al-Haider A, Abu-
aisha H: Comparison of the effects of three haemodialysis
membranes on vancomycin disposition. Int Urol Nephrol 1994,
26:223-228.
16. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA,
Sherman RA: Pharmacokinetics of vancomycin when adminis-
tered during high flux hemodialysis. Clin Nephrol 1998, 50:51-
55.
17. Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clear-
ance of vancomycin during hemodialysis using polysulfone
dialysers. Kidney Int 1989, 35:1409-1412.
18. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins
RE, Maroni BJ: Vancomycin redistribution: dosing recommen-
dations following high-flux hemodialysis. Kidney Int 1994, 45:
232-237.
19. Schaedeli F, Uehlinger DE: Urea kinetics and dialysis treatment
time predict vancomycin elimination during high-flux
hemodialysis. Clin Pharmacol Ther 1998, 63:26-38.
20. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J:
Pharmacokinetics of vancomycin in patients undergoing
hemodialysis with polyacrylonitrile. Clin Nephrol 1991, 36:35-
41.
21. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ: Van-
comycin removal by high-flux polysulfone hemodialysis mem-
branes in critically ill patients with end-stage renal disease.
Am J Kidney Dis 1995, 26:469-474.
22. Welage LS, Mason NA, Hoffman EJ, Odeh RM, Dombrouski J,
Patel JA, Swartz RD: Influence of cellulose triacetate hemodia-
lyzers on vancomycin pharmacokinetics. J Am Soc Nephrol
1995, 6:1284-1290.
23. Zoer J, Schrander-van der Meer AM, van Dorp WT: Dosage rec-
ommendation of vancomycin during haemodialysis with
highly permeable membranes. Pharm World Sci 1997, 19:191-
196.
Critical Care    August 2002 Vol 6 No 4 Launay-Vacher et al.